总部位于西雅图的Atossa万博manbetx 体育官网 Therapeutics(NASDAQ:ATOS)is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19.

Latest Financial Results

查看所有文件

Stock Info

领导

Richard I. Steinhart

Director

Steinhart先生自2014年3月以来一直担任该公司的董事。Steinhart先生目前是2015年10月至2017年6月Bioxcel Therapeutics,Inc。的副总裁兼首席财务官。,Inc。私有制药公司。从2014年1月开始,他一直加入Remedy Pharmaceuticals,Steinhart先生担任生物技术和医疗设备行业的独立财务顾问。

From April 2006 to December 2013, Mr. Steinhart was an executive at MELA Sciences, Inc., most recently serving as its Senior Vice President, Chief Financial Officer, Treasurer and Secretary. From 1992 to 2006, Mr. Steinhart was Managing Director at Forest St. Capital/SAE Ventures. Earlier, he served as Vice President and Chief Financial Officer at Emisphere Technologies from 1991 to 1992 and as General Partner and Chief Financial Officer of CW Group Inc. Mr. Steinhart is a Member of the Board of Directors of Actinium Pharmaceuticals where he is Chairman of the Audit Committee and a member of the Compensation Committee. From 2004 to 2012, Mr. Steinhart was a Member of the Board of Directors of Manhattan Pharmaceuticals and was Chairman of the Audit Committee. Mr. Steinhart received his B.B.A. and M.B.A. degrees from Pace University. Mr. Steinhart has been selected to serve on the Company’s Board of Directors because of his qualifications as a business executive and audit committee financial expert, and his prior experience as a Chief Financial Officer, director and committee member of public companies.

Gregory L. Weaver

Director

Mr. Weaver has served as a director of the Company since October 2013. Mr. Weaver is currently serving as a financial consultant for several biopharmaceutical companies. From October 2017 – March 2020, he served as Chief Financial Officer of Eloxx Pharmaceuticals, a publicly traded biotech company. From October 2015 to August 2017 he served as Chief Financial officer of ProMetic Life Sciences, a publicly traded pharmaceutical company.

从2015年1月到10月,他担任公共生物技术公司Oryzon Genomics的全球首席财务官。从2013年8月到2014年10月,Weaver先生担任公共生物技术公司Fibrocell Science,Inc。的首席财务官,高级副总裁,财务主管兼公司秘书。从2011年6月到2013年7月,Weaver先生担任首席财务官兼Celsion Corp.高级副总裁,Weaver先生获得了学士学位。Trinity University的学位和他的硕士学位学位。Weaver先生因担任业务主管和审计委员会财务专家的资格以及他当前和先前担任首席财务官,董事,委员会董事和委员会成员的资格,因此被选为公司董事会任职。Weaver先生在公共生物技术公司Egalet Corp.的董事会任职。

H. Lawrence Remmel, Esq.

Director

先生·雷梅尔已经担任主任身为公司since February 2012. He is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. Mr. Remmel joined Pryor Cashman in 1988. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas.

Mr. Remmel served on the Board of Advisors of CytoDel, LLC, an early stage bio-pharmaceutical company developing products for bio-defense, neuronal drug delivery, and musculoskeletal and aesthetic medicine. In February 2018, he became a director of CytoDel, Inc., the successor to CytoDel LLC. He was an associate of the law firm Reboul, MacMurray, Hewitt, Maynard & Kristol from 1984 to 1988, and began his legal career at Carter, Ledyard & Milburn, where he was an associate from 1979 to 1984. He was admitted to the New York bar in 1980 and is a member of the New York State Bar Association. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in hyperplasia and early stage breast cancer. Mr. Remmel has been selected to serve on the Company’s Board of Directors because of his substantial experience as a corporate attorney advising biotechnology companies and his familiarity with the fiduciary duties and the regulatory requirements affecting publicly traded companies.

Stephen J. Galli, M.D.

Director

加利博士担任公司的董事since July 2011. Dr. Galli has been a Professor of Pathology and of Microbiology & Immunology and the Mary Hewitt Loveless, M.D., Professor, Stanford University School of Medicine, Stanford, California since February 1999. He served as Chair of the Department of Pathology at Stanford University School of Medicine from 1999 to 2016. Before joining Stanford, he was on the faculty of Harvard Medical School. He holds 14 U.S. patents and has over 400 publications.

He is past president of the American Society for Investigative Pathology and past president of the Collegium Internationale Allergologicum. In addition to receiving several awards for his research, he was recognized with the 2010 Stanford University President’s Award for Excellence through Diversity for his recruitment and support of women and underrepresented minorities at Stanford University. He received his B.A. degree in biology, magna cum laude, from Harvard College in 1968 and his M.D. degree from Harvard Medical School in 1973 and completed a residency in anatomic pathology at the Massachusetts General Hospital in 1977. Dr. Galli has been selected to serve on the Company’s Board of Directors because of his qualifications as a professor and physician, and his specialized expertise as a pathologist.

Shu-Chih Chen, Ph.D.

Director

陈竺担任创始人兼director since April 2009. She served as Chief Scientific Officer of the Company since it was incorporated in April 2009 through August 2014. She was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant studying tumor suppression by gap junction protein connexin 43 at the Department of Molecular Medicine at Northwest Hospital, Seattle, WA.

She has two issued U.S. patents and 20 pending U.S. patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on molecular oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984. Dr. Chen was selected to serve on the Company’s Board of Directors because of her role as a founder of the Company and her qualifications in medical technology and as a professor and researcher in the field of cancer therapeutics.

史蒂文·奎伊(Steven C. Quay),医学博士

Chairman of the Board and Chief Executive Officer

自2009年4月公司成立以来,Quay博士一直担任公司董事会首席执行官,总裁兼董事长。哈佛医学院教学医院的马萨诸塞州综合医院解剖病理学的居留,曾是斯坦福大学医学院病理学系的前任教职员工。

Quay博士是87项美国专利,有130份美国专利申请的名称发明者,并被任命为涵盖美国食品药品监督管理局批准的五种药品的专利发明人。Quay博士于1977年获得医学博士学位和博士学位。1975年,密歇根大学。他获得了学士学位degree in biology, chemistry and mathematics from Western Michigan University in 1971. He was selected to serve on the Company’s Board of Directors because of his role as a founder of the Company, as well as his qualifications as a physician and the principal researcher overseeing the clinical and regulatory development of the Company’s pharmaceutical programs.

史蒂文·奎伊(Steven C. Quay),医学博士

Chairman of the Board and Chief Executive Officer

自2009年4月公司成立以来,Quay博士一直担任公司董事会首席执行官,总裁兼董事长。哈佛医学院教学医院的马萨诸塞州综合医院解剖病理学的居留,曾是斯坦福大学医学院病理学系的前任教职员工。

Quay博士是87项美国专利,有130份美国专利申请的名称发明者,并被任命为涵盖美国食品药品监督管理局批准的五种药品的专利发明人。Quay博士于1977年获得医学博士学位和博士学位。1975年,密歇根大学。他获得了学士学位degree in biology, chemistry and mathematics from Western Michigan University in 1971. He was selected to serve on the Company’s Board of Directors because of his role as a founder of the Company, as well as his qualifications as a physician and the principal researcher overseeing the clinical and regulatory development of the Company’s pharmaceutical programs.

Kyle Guse,Esq。,CPA。

首席财务官,总法律顾问

Mr. Guse has served as Chief Financial Officer, General Counsel and Secretary since January 2013. His experience includes more than 20 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization.

Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse previously served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte & Touche and he is a licensed Certified Public Accountant in the state of California. Mr. Guse earned a B.S. in Business Administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.

B. Heather Fraser, PhD

VP Clinical, Regulatory & CMC

Dr. Fraser brings over 20 years of extensive industry experience in the biotech industry to the Company, recently serving in a leadership role as VP Clinical Operations & Program Management at Cerecor, Inc. She held positions with increasing levels of responsibility at Anthera Pharmaceuticals and CV Therapeutics (acquired by Gilead Sciences) where the roles included preclinical and clinical sciences and regulatory affairs. Dr. Fraser has experience in drug development across diverse therapeutic areas including psychiatry, central nervous system disorders, cardiovascular disorders, and rare diseases; and she has been involved in all stages of drug development from pre-clinical through Phase 4. Dr. Fraser received her BS in Zoology from the University of British Columbia, her MS in Pharmaceutical Sciences from the University of Montana and her PhD in Pharmacology from the University of Alberta. She also completed a post-doctoral fellowship at Johns Hopkins University School of Medicine.

Delly Behen, PHR, SHRM-CP

VP, Administration & HR

Delly Behen, PHR, SHRM-CP has served as Atossa’s VP, Administration & Human Resources since July 2014. Delly brings over 20 years of human resources, administrative, and operational experience to the company. Her experience includes leading people, culture and administration at various biotech companies throughout the Puget Sound. Most recently, she served as Impel NeuroPharma’s HR Consultant, where she helped grow the company and implement HR policies and procedures. She also held positions with increasing responsibilities at CTI Biopharma. Delly received her B.A. degree from the University of Washington and her HR certification from Seattle Pacific University.

Heather Rees

Vice President, Finance and Accounting

Ms. Rees brings more than 25 years of experience in finance and accounting leadership roles within publicly traded, IPO startups and global organizations. Prior to her current role, Ms. Rees served as Atossa’s Controller from 2017 through early 2021. She previously spent ten years working as an independent financial consultant serving public and private companies including, Avalara, Getty Images, Fisher Communications, and Flow International. Heather began her career with Deloitte & Touche and worked nine years in the audit practice. Ms. Rees earned a Bachelor of Business Administration in accounting from Gonzaga University. She is a CPA in the state of Washington (inactive).

分析师覆盖范围